Arca and BlockTower Intend to Merge, Unlocking Synergies and Growth Opportunities
The industry-leading firms have signed a Letter of Intent (LOI) to enter into an all-equity deal.
"We expect to see ongoing consolidation, the emergence of new investment vehicles, and unique investment opportunities that differ from anything currently available in finance," says
"Competing in the maturing digital assets space and serving our investors requires a constant fight for top talent. By merging with Arca, we're excited to create a stronger investment team immediately," adds
Both firms have endeavored to create products to capture the evolving crypto opportunity set and to comply with regulatory standards. BlockTower and Arca each have entities that are registered investment advisers subject to SEC regulation.
"Investors have been clamoring for regulated digital assets investment offerings for years," says
About Arca
Founded in 2018, Arca is a leading financial institution in the digital asset space. The
About BlockTower Capital
BlockTower is an institutional investment management firm focused on cryptocurrency and blockchain technology, managing strategies across public and private markets, including liquid trading, venture investing, credit underwriting, and co-invest opportunities. BlockTower was founded in 2017 by former executives of Goldman Sachs and The University of Chicago Endowment. The firm has offices in
Disclosures
This communication is in no way a solicitation or an offer to sell securities or investment advisory services. Registration as an investment adviser with the U.S. Securities and Exchange Commission does not imply a certain level of skill or training.
View original content to download multimedia:https://www.prnewswire.com/news-releases/arca-and-blocktower-intend-to-merge-unlocking-synergies-and-growth-opportunities-302304081.html
SOURCE Arca; BlockTower
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nebius Group prices upsized $5B convertible notes offering
- Revelation Biosciences picks Avance Clinical for kidney injury trial
- Karman Line Acquisition closes $200M IPO on Nasdaq
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share